{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"7.6","upperLimit":"14.8","value":"11.1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"58"}],"units":"Participants"}],"description":"OS is defined as the duration from the date of enrollment to the date of death from any cause. For participants who were alive at the time of the data inclusion cutoff, OS was censored at the date of last contact prior to that cut-off date.","dispersionType":"95% Confidence Interval","groups":[{"description":"Cetuximab loading dose of 400 mg/m² administered intravenously on Day 1 of Cycle 1; subsequently 250 mg/m² administered intravenously weekly.\n\nPemetrexed 500 mg/m² administered intravenously on Day 1 of every 21-day cycle, 1 hour after cetuximab.\n\nCarboplatin AUC 5 or cisplatin 75 mg/m² administered intravenously on Day 1 of every 21-day cycle, 30 minutes after pemetrexed.\n\nMaximum 6 cycles. Participants who did not experience disease progression after 6 cycles continued on cetuximab (250 mg/m² intravenously weekly) monotherapy until disease progression.","id":"OG000","title":"Cetuximab + Pemetrexed + Carboplatin/Cisplatin"}],"paramType":"MEDIAN","populationDescription":"All treated participants excluding those from a noncompliant study site. The number of participants censored was 22.","reportingStatus":"POSTED","timeFrame":"From enrollment to the date of death from any cause up to 26.4 months (assessment completed during trial period at least every 3 months)","title":"Overall Survival (OS)","type":"SECONDARY","unitOfMeasure":"months"}